%PDF-1.7 1 0 obj << /Type /Catalog /Outlines 2 0 R /Pages 3 0 R >> endobj 2 0 obj << /Type /Outlines /Count 0 >> endobj 3 0 obj << /Type /Pages /Kids [6 0 R 13 0 R ] /Count 2 /Resources << /ProcSet 4 0 R /Font << /F1 8 0 R /F2 9 0 R /F3 10 0 R >> /ExtGState << /GS1 11 0 R /GS2 12 0 R >> >> /MediaBox [0.000 0.000 595.280 841.890] >> endobj 4 0 obj [/PDF /Text ] endobj 5 0 obj << /Producer (dompdf 3.1.0 + CPDF) /CreationDate (D:20260727144514+00'00') /ModDate (D:20260727144514+00'00') >> endobj 6 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Contents 7 0 R >> endobj 7 0 obj << /Length 5208 >> stream 0.000 0.000 0.000 rg BT 35.000 797.842 Td /F1 19.5 Tf [(Treadwell Therapeutics Announces A Presentation at the 2021)] TJ ET BT 35.000 774.033 Td /F1 19.5 Tf [(SABCS Annual Meeting Featuring a Clinical Trial Update on)] TJ ET BT 35.000 750.223 Td /F1 19.5 Tf [(CFI-402257, a Best-in-Class TTK inhibitor)] TJ ET BT 35.000 710.207 Td /F3 14.0 Tf [(Description)] TJ ET BT 35.000 669.017 Td /F1 12.0 Tf [(New York and Hong Kong ?? December 8th, 2021 ?? Treadwell Therapeutics, today announced a)] TJ ET BT 35.000 654.365 Td /F1 12.0 Tf [(presentation for the Company??s CFI-402257 program, an oral, best-in-class TTK inhibitor, at the)] TJ ET BT 35.000 639.713 Td /F1 12.0 Tf [(2021 San Antonio Breast Cancer Symposium \(SABCS\) being held from December 7-10, 2021. This)] TJ ET BT 35.000 625.061 Td /F1 12.0 Tf [(presentation will describe dose escalation and expansion data from CFI-402257-CL-001, an)] TJ ET BT 35.000 610.409 Td /F1 12.0 Tf [(investigator-initiated study of CFI-402257 in advanced solid tumors.)] TJ ET BT 35.000 583.757 Td /F1 12.0 Tf [(??The anti-tumor activity observed with CFI-402257 alone or in combination with Fulvestrant in)] TJ ET BT 35.000 569.105 Td /F1 12.0 Tf [(patients with ER+/Her2- breast cancer, including patients previously treated with CDK4/6 inhibitors, is)] TJ ET BT 35.000 554.453 Td /F1 12.0 Tf [(encouraging and warrants further investigation?)] TJ ET BT 295.124 554.453 Td /F1 12.0 Tf [()] TJ ET BT 298.460 554.453 Td /F1 12.0 Tf [( said Dr. Phillipe Bedard, Study investigator,)] TJ ET BT 35.000 539.801 Td /F1 12.0 Tf [(Associate Professor of Medicine at the University of Toronto and Staff Medical Oncologist at the)] TJ ET BT 35.000 525.149 Td /F1 12.0 Tf [(Princess Margaret Cancer Centre, Toronto, Canada. ??We look forward to additional data from this)] TJ ET BT 35.000 510.497 Td /F1 12.0 Tf [(study, as well as the initiation of our company sponsored TWT-203 trial in ER+/Her2- breast cancer,?)] TJ ET BT 577.544 510.497 Td /F1 12.0 Tf [()] TJ ET BT 35.000 495.845 Td /F1 12.0 Tf [(added Dr. Michael Tusche, Treadwell co-CEO.)] TJ ET 0.424 0.710 0.333 rg BT 184.080 469.193 Td /F1 12.0 Tf [(2021 SABCS Poster Presentations and Details:)] TJ ET BT 49.692 454.541 Td /F1 12.0 Tf [(CFI-402257-CL-001: An Open-Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-)] TJ ET BT 290.124 439.889 Td /F1 12.0 Tf [(402257)] TJ ET BT 150.084 425.237 Td /F1 12.0 Tf [(Administered Orally to Patients with Advanced Solid Tumors)] TJ ET 0.000 0.000 0.000 rg BT 241.782 410.585 Td /F1 12.0 Tf [(Poster Number: P1-18-17)] TJ ET BT 196.416 395.933 Td /F1 12.0 Tf [(Date: December 8th, 7:00 am ?? 8:30 pm)] TJ ET BT 35.000 369.281 Td /F1 12.0 Tf [(In this presentation, CFI-402257 demonstrated a tolerable safety profile at doses up to 168 mg QD and)] TJ ET BT 35.000 354.629 Td /F1 12.0 Tf [(linear pharmacokinetics, with 168 mg as the RP2D. In this heavily pre-treated, all-comer patient)] TJ ET BT 35.000 339.977 Td /F1 12.0 Tf [(population \(N=67\), 25 patients \(53.2%\) showed disease control \(SD+PR+CR\) and 5 patients showed)] TJ ET BT 35.000 325.325 Td /F1 12.0 Tf [(confirmed PRs \(10.6%\), 4 patients with ER+/Her2- breast cancer and 1 with hepatocellular carcinoma.)] TJ ET BT 35.000 310.673 Td /F1 12.0 Tf [(Two of the breast cancer patients were treated with monotherapy and two were treated in combination)] TJ ET BT 35.000 296.021 Td /F1 12.0 Tf [(with fulvestrant. The median duration of response for the breast cancer patients was 256 days with PRs)] TJ ET BT 35.000 281.369 Td /F1 12.0 Tf [(coming after only 2 cycles. The most common drug related toxicities of any grade, which occurred in)] TJ ET BT 35.000 266.717 Td /F1 12.0 Tf [(greater than 10% of patients, were nausea \(29.9%\), fatigue \(22.4%\), decreased appetite \(20.9%\),)] TJ ET BT 35.000 252.065 Td /F1 12.0 Tf [(diarrhea \(16.4%\), vomiting \(13.4%\), neutrophil count decrease \(11.9%\), alopecia \(10.4%\), neutropenia)] TJ ET BT 35.000 237.413 Td /F1 12.0 Tf [(\(10.4%\), and white blood cell count decrease \(10.4%\).)] TJ ET BT 35.000 206.728 Td /F3 14.0 Tf [(About Treadwell Therapeutics)] TJ ET BT 35.000 177.538 Td /F1 12.0 Tf [(Treadwell Therapeutics is a science driven, clinical-stage, multi-modality biotechnology company)] TJ ET BT 35.000 162.886 Td /F1 12.0 Tf [(developing first-in-class and best-in-class medicines to address unmet needs in patients with cancer.)] TJ ET BT 35.000 148.234 Td /F1 12.0 Tf [(The Company??s internally developed clinical pipeline includes CFI-400945 \(PLK4 inhibitor\), CFI-)] TJ ET BT 35.000 133.582 Td /F1 12.0 Tf [(402257 \(TTK inhibitor\), and CFI-402411 \(HPK1 inhibitor\). For more information, please visit)] TJ ET BT 35.000 118.930 Td /F1 12.0 Tf [(www.treadwelltx.com.)] TJ ET q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 1)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 8 0 obj << /Type /Font /Subtype /Type1 /Name /F1 /BaseFont /Helvetica /Encoding /WinAnsiEncoding >> endobj 9 0 obj << /Type /Font /Subtype /Type1 /Name /F2 /BaseFont /Times-Roman /Encoding /WinAnsiEncoding >> endobj 10 0 obj << /Type /Font /Subtype /Type1 /Name /F3 /BaseFont /Helvetica-Bold /Encoding /WinAnsiEncoding >> endobj 11 0 obj << /Type /ExtGState /BM /Normal /CA 1 >> endobj 12 0 obj << /Type /ExtGState /BM /Normal /ca 1 >> endobj 13 0 obj << /Type /Page /MediaBox [0.000 0.000 595.280 841.890] /Parent 3 0 R /Annots [ 15 0 R ] /Contents 14 0 R >> endobj 14 0 obj << /Length 931 >> stream 0.000 0.000 0.000 rg BT 35.000 818.176 Td /F3 14.0 Tf [(Contact)] TJ ET BT 35.000 788.986 Td /F1 12.0 Tf [(Investors:)] TJ ET 0.000 0.000 0.000 RG 0.6 w 0 J [ ] 0 d 35.000 786.376 m 87.020 786.376 l S 0.000 0.000 0.800 rg BT 35.000 774.334 Td /F1 12.0 Tf [(ir@treadwelltx.com)] TJ ET 0.000 0.000 0.800 RG 35.000 771.724 m 137.192 771.724 l S 0.000 0.000 0.000 rg BT 35.000 747.682 Td /F3 12.0 Tf [(Date Created)] TJ ET BT 35.000 733.030 Td /F1 12.0 Tf [(December 8, 2021)] TJ ET q 35.000 730.099 0.000 0.000 re W n Q /GS1 gs /GS2 gs q 35.000 52.000 m 35.000 53.000 l 585.280 53.000 l 585.280 52.000 l 585.280 50.500 l 35.000 50.500 l W n 0.502 0.502 0.502 RG 1.5 w 0 J [ ] 0 d 35.000 51.250 m 585.280 51.250 l S Q /GS1 gs /GS2 gs 0.000 0.000 0.000 rg BT 44.000 31.732 Td /F1 10.0 Tf [(Page 2)] TJ ET q 44.000 17.080 532.280 12.210 re W n BT 258.180 19.522 Td /F1 10.0 Tf [(Treadwell Therapeutics)] TJ ET Q /GS1 gs /GS2 gs endstream endobj 15 0 obj << /Type /Annot /Subtype /Link /F 28 /A 16 0 R /Border [0 0 0] /H /I /Rect [ 35.0000 772.0026 137.1920 784.2126 ] >> endobj 16 0 obj << /Type /Action /S /URI /URI (mailto:ir@treadwelltx.com) >> endobj xref 0 17 0000000000 65535 f 0000000009 00000 n 0000000074 00000 n 0000000120 00000 n 0000000344 00000 n 0000000373 00000 n 0000000522 00000 n 0000000625 00000 n 0000005885 00000 n 0000005992 00000 n 0000006101 00000 n 0000006214 00000 n 0000006271 00000 n 0000006328 00000 n 0000006452 00000 n 0000007435 00000 n 0000007568 00000 n trailer << /Size 17 /Root 1 0 R /Info 5 0 R /ID[] >> startxref 7645 %%EOF